Ulcer healing · patients with Buerger's disease
It is very uncertain whether intravenous prostacyclin analogue changes ulcer healing compared with intravenous prostaglandin analogue (very low certainty).
1 finding from 1 review
Complete relief of pain · patients with Buerger's disease
Intravenous prostacyclin analogue showed no clear difference in complete relief of pain compared with intravenous prostaglandin analogue (low certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review
All‐cause mortality (90‐day) · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes all‐cause mortality (90‐day) compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Treatment‐associated major haemorrhage ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Treatment‐associated minor haemorrhage ( · people with intermediate‐risk (submassive) APE
It is very uncertain whether ultrasound‐assisted catheter‐directed thrombolysis plus standard… changes treatment‐associated minor haemorrhage ( compared with standard intravenous heparinisation (very low certainty).
1 finding from 1 review
Recurrent APE requiring retreatment or change to a different APE treatment ( · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Length of hospital stay · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Quality of life  · people with intermediate‐risk (submassive) APE
1 finding from 1 review
Incidence of CAAs (up to 30 days) · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) probably leads to lower incidence of CAAs (up to 30 days) compared with acetylsalicylic acid (ASA) (moderate certainty).
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of fever · people undergoing initial treatment for KD
1 finding from 1 review
Need for extra treatment · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) may leads to lower need for additional treatment (up to 6 months) compared with different infusion regimens of IVIG (low certainty).
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · people undergoing initial treatment for KD
1 finding from 1 review
Mortality (all‐cause) (up to 7 weeks) · people undergoing initial treatment for KD
1 finding from 1 review
Incidence of CAAs (acute phase) · people undergoing initial treatment for KD
It is very uncertain whether primary treatment with intravenous immunoglobulin (IVIG) changes incidence of CAAs (acute phase) compared with prednisolone (very low certainty).
1 finding from 1 review
Incidence of any adverse effects after treatment initiation ( · people undergoing initial treatment for KD
Primary treatment with intravenous immunoglobulin (IVIG) showed no clear difference in incidence of any adverse effects after treatment initiation (up to 3… compared with prednisolone (low certainty).
1 finding from 1 review
Acute coronary syndrome · people undergoing initial treatment for KD
1 finding from 1 review
Fever clearance time · people undergoing initial treatment for KD
1 finding from 1 review